Skip to main content

Month: August 2025

DallasNews Rejects Revised Non-Binding Proposal from Affiliate of Alden Global Capital

Board Reaffirms Unanimous Support for the Hearst Merger and the Certain and Significant Cash Premium It Will Deliver for Shareholders DALLAS, Aug. 27, 2025 (GLOBE NEWSWIRE) — DallasNews Corporation (Nasdaq: DALN) (the “Company” or “DallasNews”), the holding company of The Dallas Morning News and Medium Giant, announced today that its Board of Directors (the “Board”), following consultation with the Company’s legal and financial advisors, reviewed and rejected the revised, non-binding proposal (the “Revised Alden Proposal”) received on August 19, 2025, from MNG Enterprises, Inc., an affiliate of Alden Global Capital (“Alden”), to acquire all of the issued and outstanding shares of the Company’s common stock at $18.50 per share in cash. As previously announced, on July 9, 2025, DallasNews entered into a definitive agreement (as amended...

Continue reading

NanoXplore to Host a Webcast to Discuss Fourth Quarter and Year End Results on September 17th, 2025 

MONTREAL, Aug. 27, 2025 (GLOBE NEWSWIRE) — NanoXplore Inc. (“NanoXplore”) (TSX: GRA and OTCQX: NNXPF) is pleased to hold a webcast to discuss the results of its fourth quarter and year end results ended June 30, 2025, on Wednesday, September 17, 2025, at 10:00 a.m. Eastern Time. The financial results will be released on Tuesday, September 16, 2025, after the market close.    Details of the Q4 Webcast   When: September 17, 2025, at 10:00 a.m. Eastern Time   Webcast: To listen to the live webcast, please join and register at:   https://edge.media-server.com/mmc/p/sgme9spg or via our website under Events and Presentations in our Investors section at www.nanoxplore.ca   A replay of the event will be available at the above webcast link or in the Investors section under Events and Presentations of the Company’s website at www.nanoxplore.ca.    About...

Continue reading

MasterCraft Boat Holdings, Inc. Reports Fiscal 2025 Results

VONORE, Tenn., Aug. 27, 2025 (GLOBE NEWSWIRE) — MasterCraft Boat Holdings, Inc. (NASDAQ: MCFT) today announced financial results for its fiscal 2025 fourth quarter and year ended June 30, 2025. The overview, commentary, and results provided herein relate to our continuing operations, which consists of our MasterCraft and Pontoon segments. Fourth Quarter Overview:Net sales for the fourth quarter were $79.5 million, up $25.2 million, or 46.4%, from the comparable prior-year period Income from continuing operations was $5.5 million, or $0.33 per diluted share Adjusted Net Income, a non-GAAP measure, was $6.6 million, or $0.40 per diluted share Adjusted EBITDA, a non-GAAP measure, was $9.5 million, up $8.0 million from the comparable prior-year period Share repurchases of $4.5 million during the quarterFull Year Overview:Net...

Continue reading

Abercrombie & Fitch Co. Reports Second Quarter Fiscal 2025 Results

Delivers 11th consecutive quarter of growth, with record net sales of $1.2 billion, up 7% from last year, exceeding outlook Net sales growth led by Americas up 8%, APAC up 12%, partially offset by 1% decline in EMEA Hollister brands delivers its best ever second quarter net sales on growth of 19%, with Abercrombie brands down 5% Second quarter operating margin of 17.1% and earnings per share of $2.91 include a litigation settlement benefit of $39 million on pre-tax basis, $0.59 per share benefit on tax-adjusted basis Excluding favorable litigation settlement impact, second quarter adjusted operating margin of 13.9% and adjusted EPS of $2.32 exceeded outlook Increases full-year net sales outlook, with profitability update incorporating current $90 million estimate of net tariff cost impactNEW ALBANY, Ohio, Aug. 27, 2025 (GLOBE NEWSWIRE)...

Continue reading

Pasinex Announces Q2 2025 Financial Results and Provides Corporate Update

TORONTO, Aug. 27, 2025 (GLOBE NEWSWIRE) — Pasinex Resources Limited (CSE: PSE) (FSE: PNX) (“Pasinex” or the “Company”) today announced financial results for the second quarter ended June 30, 2025. The financial statements, management’s discussion and analysis (MD&A), and related certifications are available on SEDAR+. Highlights                                   Three Months Ended       Six Months Ended              June 30,       June 30,            2025     2024     2025     2024    Financial:                      Share of net equity gain from joint venture   $ 18,633   $ 309,802   $ 61,413   $ 943,280      Consolidated net (loss) income   $ (282,935 ) $ (296,550 ) $ (1,171,412 ) $ (10,778 )    Basic and diluted (net) income per share   $ (0.002 ) $ (0.002 ) $ (0.008 ) $ (0.000 )    Net...

Continue reading

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that management will participate in webcast fireside chats at the following investor conferences: Wells Fargo Healthcare Conference Date/Time: Wednesday, September 3, 2025 at 8:45 a.m. ET Cantor Global Healthcare Conference Date/Time: Thursday, September 4, 2025 at 8:35 a.m. ET Baird Global Healthcare ConferenceDate/Time: Tuesday, September 9, 2025 at 10:15 a.m. ET The live conference webcasts will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcasts will be available for approximately 30 days following the event. About ApellisApellis Pharmaceuticals, Inc. is a global biopharmaceutical company leading the way in complement science to develop...

Continue reading

Voyageur Mineral Explorers Corp. and Evolve Strategic Element Royalties Ltd. Enter into Definitive Agreement to Complete Reverse Take-Over

Not for distribution to United States newswire services or for release publication, distribution or dissemination, directly or indirectly, in whole or in part, in or into the United States. TORONTO, Aug. 27, 2025 (GLOBE NEWSWIRE) — Voyageur Mineral Explorers Corp. (CSE: VOY) (“Voyageur” or the “Company”) and Evolve Strategic Element Royalties Inc. (“Evolve”) are pleased to announce that the parties have entered into a definitive business combination agreement dated August 26, 2025 (the “Definitive Agreement”), whereby Voyageur will acquire all of the issued and outstanding common shares of Evolve by way of a statutory three-cornered amalgamation under the Business Corporations Act (British Columbia). Upon completion of the proposed business combination (the “Proposed Transaction”), Voyageur (as it exists upon completion of the...

Continue reading

Photronics Reports Third Quarter Fiscal 2025 Financial Results

BROOKFIELD, Conn., Aug. 27, 2025 (GLOBE NEWSWIRE) — Photronics, Inc. (NASDAQ:PLAB), a worldwide leader in photomask technologies and solutions, today reported financial results for its third quarter of fiscal year 2025 ended August 3, 2025. Commenting on the third-quarter performance, Chairman and CEO George Macricostas said, “Photronics delivered very good results in our fiscal third quarter with revenue, profitability and EPS ahead of expectations. Looking ahead, we remain focused on operational efficiency to maintain our excellent standard of maximizing customer cycle times. We will further accelerate internal investment efforts to enhance geographic revenue diversification and position the company for sustained revenue and earnings growth.” Third Quarter Fiscal 2025 ResultsRevenue was $210.4 million, down 0.3% year-over-year...

Continue reading

Minovia Therapeutics Announces $350,000 Grant from Countdown for a Cure Foundation to Develop Mitochondria Blood-Based Biomarkers

HAIFA, Israel, Aug. 27, 2025 (GLOBE NEWSWIRE) — Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces that it has been chosen to receive a $350,000 grant from Countdown for a Cure for a research proposal related to the development of novel mitochondrial blood-based biomarkers. Minovia Chief Scientific Officer Dr. Noa Sher, commented, “We are grateful to the Countdown for a Cure Foundation, whose funds are expected to be instrumental in our advancing development of blood-based functional mitochondrial biomarkers. These biomarkers will enable identification of patients who may benefit from our mitochondrial augmentation technology, or MAT, proprietary platform, as well as patient follow-up...

Continue reading

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) — Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that Company executives will participate in the following upcoming investor conferences:2025 Wells Fargo Healthcare ConferenceLocation: Boston, MADate: Friday, September 5, 2025Time: 11:00-11:35 AM EDTMorgan Stanley 23rd Annual Global Healthcare ConferenceLocation: New York, NYDate: Monday, September 8, 2025H.C. Wainwright 27th Annual Global Investment ConferenceLocation: New York, NYDate: Monday, September 8, 2025A webcast of the Wells Fargo presentation will be available in the Investors and News section of the Ventyx website at www.ventyxbio.com....

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.